Northwest Biotherapeutics | NWBO - Interest Expense On Debt


Northwest Biotherapeutics reported $1.52M in Interest Expense on Debt for its fiscal quarter ending in March of 2024.





Interest Expense On Debt Change Date
Agenus USD 12.8M 7.89M Mar/2025
AstraZeneca USD 484M 181M Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Eisai JPY 1.43B 12M Dec/2025
Infinity Pharmaceuticals USD 45K 0 Jun/2023
Merck USD 412M 85M Dec/2025
Northwest Biotherapeutics USD 1.52M 276K Mar/2024
Pfizer USD 711M 59M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025